Posttransplant anemia: The role of sirolimus

Steven Fishbane, David J. Cohen, Daniel W. Coyne, Arjang Djamali, Ajay K. Singh, Jay B. Wish

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Posttransplant anemia is a common problem that may hinder patients quality of life. It occurs in 12 to 76% of patients, and is most common in the immediate posttransplant period. A variety of factors have been identified that increase the risk of posttransplant anemia, of which the level of renal function is most important. Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia. This review considers anemia associated with sirolimus, including its presentation, mechanisms, and management.

Original languageEnglish
Pages (from-to)376-382
Number of pages7
JournalKidney International
Issue number4
StatePublished - Aug 2009


  • Anemia
  • MTOR
  • Posttransplant
  • Renal
  • Sirolimus


Dive into the research topics of 'Posttransplant anemia: The role of sirolimus'. Together they form a unique fingerprint.

Cite this